Eye­Bio tar­gets reg­is­tra­tional tri­al af­ter ear­ly suc­cess of Wnt ag­o­nist in reti­nal dis­eases

Eye­Bio’s tri-spe­cif­ic Wnt ag­o­nist an­ti­body im­proved vi­su­al and anatom­i­cal mea­sures in a Phase Ib/IIa tri­al as a monother­a­py and in com­bi­na­tion with Re­gen­eron’s Eylea, prompt­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER